Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Not Yet Opened 01-23 16:00:00 EST

6.14

-0.21

-3.31%

盘后6.12

-0.02-0.33%

18:44 EST

High6.50	Low6.01	Vol755.56K
Open6.41	D1 Closing6.35	Amplitude7.72%
Mkt Cap199.68M	Tradable Cap138.93M	Total Shares32.52M
T/O4.64M	T/O Rate3.34%	Tradable Shares22.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":6.14,"timestamp":1769202000000,"preClose":6.35,"halted":0,"volume":755563,"hourTrading":{"tag":"盘后","latestPrice":6.12,"preClose":6.14,"latestTime":"18:44 EST","volume":3001,"amount":18421.6756,"timestamp":1769211853450,"change":-0.02,"changeRate":-0.003257,"amplitude":0.02057},"delay":0,"changeRate":-0.03307086614173228,"floatShares":22626486,"shares":32521599,"eps":-1.786134,"marketStatus":"Not Yet Opened","change":-0.21,"latestTime":"01-23 16:00:00 EST","open":6.41,"high":6.5,"low":6.01,"amount":4637470.6300529,"amplitude":0.077165,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.786134,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":0,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":6.35,"preHourTrading":{"tag":"盘前","latestPrice":6.4134,"preClose":6.35,"latestTime":"09:19 EST","volume":1934,"amount":12520.4272538,"timestamp":1769177979265,"change":0.0634,"changeRate":0.009984,"amplitude":0.008913},"postHourTrading":{"tag":"盘后","latestPrice":6.12,"preClose":6.14,"latestTime":"18:44 EST","volume":3001,"amount":18421.6756,"timestamp":1769211853450,"change":-0.02,"changeRate":-0.003257,"amplitude":0.02057},"volumeRatio":2.207204312902537,"impliedVol":1.1289,"impliedVolPercentile":0.2072},"requestUrl":"/m/hq/s/SGMT/tweets","defaultTab":"tweets","newsList":[{"id":"2602305637","title":"Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2602305637","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602305637?lang=en_us&edition=fundamental","pubTime":"2026-01-10 02:35","pubTimestamp":1767983740,"startTime":"0","endTime":"0","summary":"In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Sagimet Biosciences, Inc. Class A, with a price targe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sagimet-biosciences-advancing-fasn-inhibitor-pipeline-and-multi-indication-opportunities-support-buy-rating-and-26-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sagimet-biosciences-advancing-fasn-inhibitor-pipeline-and-multi-indication-opportunities-support-buy-rating-and-26-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2601369845","title":"Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369845","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369845?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873600,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Jan.  08, 2026  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215214/0/en/Sagimet-Biosciences-Announces-Poster-Presentation-at-the-10th-Annual-MASH-TAG-2026-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2592490843","title":"Sagimet Biosciences Reports Positive Phase 1 Results for Denifanstat and Resmetirom Combination in MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2592490843","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592490843?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:00","pubTimestamp":1766059216,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. announced positive results from a Phase 1 pharmacokinetic  clinical trial evaluating the combination of its oral fatty acid synthase  inhibitor, denifanstat, with the thyroid hormone receptor beta  agonist, resmetirom. The study enrolled 40 healthy adult participants and assessed the safety, tolerability, and potential drug-drug interactions of the combination. The results indicated that the combination was generally well-tolerated, with no serious adverse events or treatment discontinuations reported. These Phase 1 results have already been presented, and Sagimet plans to advance the combination into a Phase 2 proof-of-concept efficacy trial for patients with metabolic dysfunction-associated steatohepatitis  with F4 fibrosis, expected to initiate in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL50FP5d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","BK4585","BK4588","BK4139","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","SG9999014021.USD","SG9999014005.SGD","SGMT","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2592908195","title":"Sagimet Biosciences Inc - Plans Phase 2 Trial for Mash With F4 Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592908195?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:00","pubTimestamp":1766059202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA8H9W22:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2592908144","title":"Sagimet Biosciences Inc - Combination Well-Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908144","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592908144?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:00","pubTimestamp":1766059202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA8H9W22:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2592908113","title":"Sagimet Biosciences Inc - Phase 2 Trial to Start in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592908113?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:00","pubTimestamp":1766059202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA8H9W22:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2592790814","title":"Sagimet Biosciences Announces Positive Results From the Phase 1 Pk Clinical Trial of Denifanstat and Resmetirom Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2592790814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592790814?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:00","pubTimestamp":1766059202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA8H9W22:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2592826914","title":"Sagimet Biosciences Shares Rise on Licensing Agreement With Teva","url":"https://stock-news.laohu8.com/highlight/detail?id=2592826914","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592826914?lang=en_us&edition=fundamental","pubTime":"2025-12-18 00:23","pubTimestamp":1765988580,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences shares rose after the company said it had entered into a global licensing agreement.The stock rose 13% to $6.83 on Wednesday. Shares are up 48% this year.The San Mateo, Calif., biopharmaceutical company said Wednesday it signed an agreement with Assia Chemical Industries, doing business as TAPI, which is a subsidiary of Teva Pharmaceutical Industries.Under the agreement, Sagimet will have a global exclusive license to certain intellectual property rights covering forms of the active pharmaceutical ingredient in TAPI's drug resmetirom.The rights will be used for Sagimet's technical evaluation and manufacture, as well as potential further development of a fixed-dose combination product containing denifanstat and resmetirom.Sagimet is developing trials to see if the combined drugs can effectively treat adults with metabolic dysfunction-associated steatohepatitis .The company plans to move the trial into phase 2 in the second half of 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4585","SGMT","BK4007","BK4559","BK4584","BK4588","LU1983299246.USD","TEVA","BK4139","BK4557","BK4596"],"gpt_icon":0},{"id":"2592992883","title":"Sagimet Biosciences Secures Global License for Innovative Resmetirom API from TAPI","url":"https://stock-news.laohu8.com/highlight/detail?id=2592992883","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592992883?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972835,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. has announced a global, exclusive license agreement with TAPI Technology & API Services , a subsidiary of Teva Pharmaceutical Industries Ltd. Under the agreement, Sagimet will have access to innovative forms of resmetirom active pharmaceutical ingredient  developed by TAPI, which are covered by TAPI patent applications. The collaboration will support Sagimet's fixed-dose combination  program that combines denifanstat and resmetirom, with a Phase 1 pharmacokinetic trial underway and topline data expected by the end of 2025. Sagimet plans to select one of the licensed resmetirom forms for further development in a Phase 3 FDC tablet targeting cirrhosis of the liver, an area with high medical need and currently no approved therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL701K4p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4139","LU2210150020.SGD","SG9999014013.SGD","SGMT","BK4585","BK4588","LU2210149790.SGD","NDAQ","SG9999014039.USD","BK4112"],"gpt_icon":0},{"id":"2592994026","title":"Sagimet Biosciences and Tapi Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994026","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592994026?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA7SJBHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2592992630","title":"Sagimet Biosciences - Trial of Combination of Denifanstat & Resmetirom Is Underway With Topline Data Anticipated by 2025 End","url":"https://stock-news.laohu8.com/highlight/detail?id=2592992630","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592992630?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA7SJBHG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2590058233","title":"BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat","url":"https://stock-news.laohu8.com/highlight/detail?id=2590058233","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590058233?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:43","pubTimestamp":1765370632,"startTime":"0","endTime":"0","summary":"BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat Dec 10 (Reuters) - Sagimet Biosciences Inc SGMT.O:SAGIMET’S LICENSE PARTNER ASCLETIS ANNOUNCED ACC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA3RPNQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2590584346","title":"Sagimet Biosciences Inc - Grants Exclusive License to Denifanstat for China to Ascletis","url":"https://stock-news.laohu8.com/highlight/detail?id=2590584346","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590584346?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:03","pubTimestamp":1765368223,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA3RPNQJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2590581783","title":"Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2590581783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590581783?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:03","pubTimestamp":1765368223,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA3RPNQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2590432142","title":"Sagimet Biosciences Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2590432142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590432142?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:05","pubTimestamp":1765314308,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. has approved inducement grants totaling 42,800 stock options for three newly hired employees. The options, to be granted on December 9, 2025, will have an exercise price equal to the closing price of Sagimet's Series A common stock on that date. The options have a ten-year term and will vest over four years: 25% on the one-year anniversary of employment commencement, with the remaining shares vesting monthly over the following 36 months, contingent on continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on December 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLbksC7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2210150020.SGD","LU2095319765.USD","BK4139","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","SGMT","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2590322888","title":"Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590322888","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590322888?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:05","pubTimestamp":1765314300,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Dec.  09, 2025  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202776/0/en/Sagimet-Biosciences-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2587573606","title":"Buy Rating for Sagimet Biosciences: Promising Pipeline Developments and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2587573606","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587573606?lang=en_us&edition=fundamental","pubTime":"2025-11-29 00:05","pubTimestamp":1764345930,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on SGMT stock, giving a Buy rating on November 25. Debanjana Chatterj...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-sagimet-biosciences-promising-pipeline-developments-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-sagimet-biosciences-promising-pipeline-developments-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2585121708","title":"Executive Chairman George Kemble Reports Sale of Sagimet Biosciences Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585121708","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585121708?lang=en_us&edition=fundamental","pubTime":"2025-11-22 07:13","pubTimestamp":1763766829,"startTime":"0","endTime":"0","summary":"George Kemble, Executive Chairman of Sagimet Biosciences Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL2QqQ7p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Executive Chairman George Kemble Reports Sale of Sagimet Biosciences Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2584413629","title":"Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584413629","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584413629?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:00","pubTimestamp":1763640000,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Nov.  20, 2025  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3191757/0/en/Sagimet-Biosciences-to-Participate-in-the-8th-Annual-Evercore-ISI-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4139","SGMT","LU0029874061.USD","XLV","LU0128526141.USD","HCSG","BK4588","LABU","BK4585","XBI","BK4137"],"gpt_icon":0},{"id":"2583500346","title":"Sagimet Biosciences Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2583500346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583500346?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:38","pubTimestamp":1763134680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 10:38 ET (15:38 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0132},{"period":"3month","weight":-0.3282},{"period":"6month","weight":-0.4004},{"period":"1year","weight":0.4795},{"period":"ytd","weight":0.0372}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}